Abstract
The combination of carboplatin and etoposide has been tested in intraocular retinoblastoma (IORB), in order to avoid enucleation or radiotherapy and to permit local therapy.
Seventeen patients with intraocular RB have been treated with Carboplatin (1000 mg/sqm) and Etoposide (300mg/sqm) on day 1, at intervals of 21–28 days and reduced by 1/3 in patients weighing less than 10–12 kg. Patients younger than 6 months received carboplatin at a dose of 25 mg/kg and etoposide at a dose of 7 mg/kg.
The disease-free survival was 91.7% with an average follow-up of 21.3 months.
After 2-4 courses of chemotherapy tumor regression was observed in 13 patients (76.5%). All patients received Argon-Laser therapy, after chemotherapy. A complete response has been observed in 52.9% of patients. Seven patients relapsed, three of whom received further courses of chemotherapy with carboplatin+etoposide obtaining a complete response.
-
In 76.5% of the cases, the administration of carboplatin+etoposide resulted in a mass shrinkage
-
In 31.2% of the cases neither enucleation nor radiotherapy were administered
-
carboplatin+etoposide was effective also in relapsed patients
-
Longer follow-up is needed on account of the risk of a second cancer
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Reese AG, Merriam GL, Martin HE: Treatment of bilateral retinoblastoma by irradiation and surgery. Report on 15 years results. Am J Ophthalmol 32: 175, 1949.
Ellesworth RM: The practical management of retinoblastoma. Trans Am Ophthalmol Soc 67: 462–534, 1969.
Morgan G: Diffuse infiltrating retinoblastoma. Br J Ophthalmol 55: 600–606, 1971.
Kingstone JE, Hungerford JL: Retinoblastoma. In: Plowman PN, Pinkerton CK (eds) Pediatric Oncology. London, Chapman & Hall Medical, p. 268–290, 1992.
Shields JA, Shields CL: Current management of retinoblastoma. Mayo Clin Proc 69: 50–56, 1994.
Donaldson SS, Egberth PR, Newsham I, Cavenee WK: Retinoblastoma. In: Pizzo R Poplack D (eds) Philadelphia, Lippincott Raven p.699, 1997.
Abramson DH, Ellesworth RM, Rozakis GW: Cryotherapy for retinoblastoma. Arch Ophthalmol 100: 1253, 1982.
Abramson DH: Cryotherapy in retinoblastoma. In: Jacobiec, ed. Technique in ophthalmic surgery. Philadelphia, WB Saunders, p.433, 1984.
Lemerle J, Bloch-Michel E: Chemotherapy in retinoblastoma: preliminary report and warning. In: Lommatzsch PK, Blody FC (eds) Intraocular tumors. New York, Springer-Verlag, p.541, 1983.
Pratt CB, Crom DB, Howard C: The use of chemotherapy for extraocular retinoblastoma. Med Pediatr Oncol 13: 330–333, 1985.
Castello MA, Clerico A, Deb G et al.: High dose Carboplatin in combination with Etoposide for childhood brain tumors. Am J Pediatr Hematol Oncol 12: 297–300, 1990.
Lee White: Chemotherapy for retinoblastoma: where do we go from here? Ophthalmic Pediatr and Genetics 12(3): 115–130, 1991.
Doz F, Quintana E, Michon J: High dose chemotherapy using VP 16, carboplatin and cyclophos-phamide with autologous bone marrow transplantation (ABMT) rescue in 9 children with extraocular retinoblastoma. Proc Am Soc Clin Oncol 11: 371, 1992 (abstr1282).
Doz F, Neuenschwander S, Plantaz D, Courbon B, Gentet JC, Bouffet E, Masseri V, Vannier JP, Mechinaud F, Desjardins L, Vielh P, Zucker JM: Etoposide and carboplatin in extraocular retinoblastoma: a study by the Société Française d’Oncologie Pédiatrique. J Clin Oncol 13(4): 902–909, 1995.
Shields JA, Augsberger JJ: Current approaches to diagnosis and management of retinoblastoma. Surv Ophthalmol 25: 347–371, 1981.
Sanders BM, Draper GJ, Kingston JE: Retinoblastoma in Great Britain, 1969-80. Incidence, treatment, and survival. Br J Ophthalmol 72: 516–583, 1988.
Malogolowkin M, Steele D, Deegan W, J. Ortega, and L. Murphee Systemic chemotherapy (CRX) for intraocular retinoblastoma (IO-RB). Proc Am Soc Clin Oncol 14: 449, 1995 (abstr1437).
Seregard S, Kock E, Trampe E: Intravitreal chemotherapy for recurrent retinoblastoma in an only eye. Br J Ophthalmol 79: 194, 1995.
Castello MA, Schiavetti A, Ragni G, Hadjistilianou T, Clerico A, Properzi E, Frezzotti R: Chemotherapy with etoposide and carboplatin in intraocular retinoblastoma. Med Pediatr Oncol 27(4): 257, 1996.
Castello MA, Schiavetti A, Ragni G, Hadjistilianou T, Clerico A, Properzi E, Cappelli C, Frezzotti R: Primary chemotherapy in intraocular retinoblastoma with carboplatin and etoposide. Med Pediatr Oncol 29(5): 414, 1997.
Shields CL, De Potter P, Himelstein BP, Shields JA, Meadows AT, Maris JM: Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol. 114: 1330–1338, 1996.
Doz F, Desjardins L, Quintana E, Levi C, Zucker JM: Efficacy and toxicity of neoadjuvant chemotherapy using etoposide and carboplatin in 20 patients with intraocular retinoblastoma. Med Pediatr Oncol 27(4): 257, 1996.
Greenwald MJ, Strauss LC: Treatment of intraocular retinoblastoma with carboplatin and etoposide chemotherapy. Ophthalmology 103(12): 1989, 1996.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Castello, M.A. et al. (1999). Combination of Carboplatin and Etoposide in The Management of Intraocular Retinoblastoma. In: Abraham, N.G., Tabilio, A., Martelli, M., Asano, S., Donfrancesco, A. (eds) Molecular Biology of Hematopoiesis 6. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4797-6_20
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4797-6_20
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7173-1
Online ISBN: 978-1-4615-4797-6
eBook Packages: Springer Book Archive